13 results
424B4
CGTX
Cognition Therapeutics Inc
14 Nov 22
Prospectus supplement with pricing info
6:02am
or distribution;
we may be required to conduct additional clinical trials or post-approval studies;
we may be required to recall a product or change the way … ; or
seize or detain products, or require a product recall.
Any government investigation of alleged violations of law could require us to expend
DRS
CGTX
Cognition Therapeutics Inc
20 Oct 22
Draft registration statement
12:00am
to conduct additional clinical trials or post-approval studies;
we may be required to recall a product or change the way such product is administered … products, or require a product recall.
Any government investigation of alleged violations of law could require us to expend significant time
10-K
2021 FY
CGTX
Cognition Therapeutics Inc
30 Mar 22
Annual report
7:40am
ability to recall fear-inducing triggers and its performance in a maze. The mice exhibiting symptoms of AD, depicted by the red bars in the image below … manufacture or distribution;
we may be required to conduct additional clinical trials or post-approval studies;
we may be required to recall a product
10-Q
143w8elk39d3nzylk
17 Nov 21
Quarterly report
5:15pm
424B4
b5rdb4b8lygfqepgql
12 Oct 21
Prospectus supplement with pricing info
4:11pm
S-1
o73wdeb
19 Jul 21
IPO registration
7:02am
DRS/A
ip539 dunuvfa
23 Jun 21
Draft registration statement (amended)
12:00am
DRS
z8gplw3a y2zqk5itt
7 May 21
Draft registration statement
12:00am
- Prev
- 1
- Next